EP0294380A1 - Stimulation de l'angiogenese - Google Patents

Stimulation de l'angiogenese

Info

Publication number
EP0294380A1
EP0294380A1 EP87901278A EP87901278A EP0294380A1 EP 0294380 A1 EP0294380 A1 EP 0294380A1 EP 87901278 A EP87901278 A EP 87901278A EP 87901278 A EP87901278 A EP 87901278A EP 0294380 A1 EP0294380 A1 EP 0294380A1
Authority
EP
European Patent Office
Prior art keywords
modulator
proline
angiogenesis
composition according
cis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP87901278A
Other languages
German (de)
English (en)
Other versions
EP0294380A4 (fr
Inventor
Brian Richard Mcauslan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biota Scientific Management Pty Ltd
Original Assignee
Biota Scientific Management Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biota Scientific Management Pty Ltd filed Critical Biota Scientific Management Pty Ltd
Publication of EP0294380A1 publication Critical patent/EP0294380A1/fr
Publication of EP0294380A4 publication Critical patent/EP0294380A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone

Definitions

  • This invention relates to the control of angiogenesis, and methods and compositions therefor.
  • a method for stimulating angiogenesis in a mammal characterized by the use of a modulator of collagen synthesis or of collagen fibril assembly.
  • Cis-HYPRO will prevent this migration of cells into the wound
  • cis-HYPRO will stimulate the migration of capillary endothelial cells in vitro. I have also fund that cis-HYPRO stimulates angiogenesis in vivo in the rabbit corneal pocket assay.
  • proline analogues may also be useful. It appears that, in general, agents which modulate collagen synthesis or collagen fibril assembly orwhich inhibit proline hydroxylase will cause the production of defective collagen which is more susceptible to degradation by proteases. Capillary endothelial cells migrate along the gradient of inhibitor concentration, and form capillary tubules in vivo despite the defect in the collagen which is synthesized.
  • a method of stimulating angiogenesis in a mammal characterized by the use of a modulator of collagen synthesis or of collagen fibril assembly.
  • the modulator is an inhibitor of the activity of the enzyme proline hydroxylase.
  • the inhibitory agent is selected from the group which includes cis-4-h droxy-L-proline, 3, 4-dehydro-L-proline, L-azetidine-2-carboxylic acid, L-proline analogues, and their pharmacologically active analogues and derivatives. n the invention may optionally be used.
  • Combinations of one or more compounds according to the present invention together with one or more compounds according to my copending Australian provisional application PH7521 entitled “Stimulation of Angiogenesis and Control of Endothelialisation” or other stimulators of angiogenesis may also optionally be used.
  • the compound according to the invention may optionally be administered in a slow-release form or in a biodegradable matrix.
  • Proliferation of endothelial cells is thought to be a response secondary to cell migration during new vessel formation.
  • the proliferative responses have been marginal and the reports are not in accord as to the minimal conditions or cell type necessary.
  • Having used one or other of the above assays to purify fractions they are usually confirmed as angiogenic by an indirect in vivo assay of activity such as the corneal pocket or chorioallantoic membrane assay.
  • proline analogues cis-4-hydroxy-L-proline (cis-HYPRO), 3, 4-dehydro-L-proline (dHPro), cis-4-hydroxy-D-proline (cisdPro) and L-azetidine-2-carboxylic acid (AZET) were obtained from Sigma Chemical Co., St. Louis, U.S.A.. To remove metal ions, they were dissolved in distilled water, applied to a column of Chelex 100 (Biorad), developed in quartz glass double distilled water, then recrystallized. This reduced the copper level to less than 0.06 parts per billion.
  • mp antat on was v a a rocar, an was per orme so as to avoid trauma to the vascular system.
  • Controls showed no overt inflammatory response and no sign of inducing angiogenesis in surrounding tissue.
  • implants were examined in situ, photographed then excised and examined histologically.
  • Corneal Pocket Assay The corneal pocket assay of Gimbrone et al (1974) as modified by Gol ' e and McAuslan (1981) was used on New Zealand white rabbits of 2 - 3 kg body weight. Opposite eyes of each
  • a line of bovine retinal capillary endothelial cells free from mural cells was established .essentially by the procedures of Buzney and Massicotte (1979).
  • Bovine corneal endothelial cell cultures were prepared and maintained as described by McAuslan et al (1979). Cultures of bovine retinal microvascular pericytes (mural cells) were established from bovine retinal capillaries by the method of Gitlin and D'Amore and maintained in Ham's F12 medium. All cell lines for experimentation on migration were used between their 8th and 12th passage. Each cell line was tested in its preferred growth medium but with the serum concentration reduced to 2%.
  • ⁇ > - ⁇ -4 per cm were treated with cis-HYPRO at 0, 10 or 5 x 10 M for 4 hours in normal growth medium. . The medium was removed and the cell layers were washed and covered with medium containing the appropriate concentration of cis-HYPRO and free of serum. This was supplemented with sodium ascorbate (50 ug/ml) and ⁇ -amino propionitrile (80 ⁇ g/ml). Then cells were (specific activity) per ml of proline free medium 199 (Commonwealth Serum Labs) . Polypeptides secreted into the medium were harvested, separated by sodium dodecylsulphate polyacrylamide gel electrophoresis and detected by autoradiography.
  • Figure 1 represents the effects of proline analogues on the growth of bovine aortal endothelial cells
  • Figure 2 represents the effects of proline analogues on the growth of bovine retinal capillary endothelial cells
  • Figure 3 represents the effects of proline analogues on the growth of bovine retinal microvascular pericytes
  • bovine retinal endothelial cells Cultures of bovine retinal endothelial cells, bovine aortic endothelial cells, and bovine retinal pericytes (mural cells) were prepared as described above, and tested separately for their response to cis-HYPRO, cis-4-hydroxy-D-proline, and L-azetidine-2-carboxylic acid. The results were normalised for each experiment as follows:
  • control was assigned .a value of 100%.
  • e resu s o an exper m n endothelial cells and retinal pericytes are shown in Table 1, in which each figure represent the mean value for 200 individual cells analysed 48 hours after the addition of the test compound.
  • the medium was Ham's F12 medium containing 5% serum (v/v). Each agent was used at a concentration of 10- M.
  • Control 13 152 7 106 cis-HYPRO 46.4 258 21.4 180 cis-D-hydroxyproline 13 152 - -
  • Cis-HYPRO strongly stimulated migration of both cell types, while cis-D-hydroxyproline had no effect, and azetidine had a marginal effect on retinal endothelial cells; dehydroproline had a small effect on retinal endothelial cells, and a stronger effect on retinal pericytes.
  • Cis-HYPRO and azetidine were assayed in rabbits using the corneal pocket assay and the subcutaneous assay as described above. The results are presented in Table 2. The figures represent the ratio of animals giving a positive angiogenic response to the total number of animals tested.
  • Cis-HYPRO caused stimulation of angiogenesis in' both systems, whereas azetidine caused stimulation only in the subcutaneous assay.
  • responses in the corneal pocket assay were weak, and the subcutaneous assay was found to be reproducible and effective for a number of chemically different angiogenic agents.
  • HYPRO or AZET were tested in a further experiment using this assay, both gave positive angiogenic responses in each of 12 tests in 6 different test animals.
  • dHPro was not found to be active.
  • epidermal growth factor (EGF; Ben-Ezra, 1978) can be explained by its ability to induce capillary endothelial cell migration and proliferation highly potent inducer and is less active angiogenically than other growth factors such as transforming growth factor TGF- (Schreiber et al, 1986). Therefore we tested the possibility that the responses produced by Cis-HYPRO and EGF might be additive.
  • the induction of bovine corneal endothelial cell migration by EGF, Cis-HYPRO or EGF plus Cis-HYPRO was compared. As shown in Table 5, the migration-inducing ability of EGF and Cis-HYPRO was at least additive over the limited range tested.
  • EGF (lOO ⁇ g/ml) 116.0 cis-HYPRO (10 ⁇ 5 M) 56.4 EGF (100 ⁇ g/ml) + cis-HYPRO (10 ⁇ 5 M) 266.7
  • cis-HYPRO or other proline analogues could be used to enhance the angiogenic effect of EGF, or of the active subunit of EGF which is responsible for angiogenesis.
  • Cis-HYPRO and other analogues work as positive effectors (e.g. causing formation of a migration peptide or enhancing the activity of a specific protease) or as negative effectors (e.g. by impairing formation of a critical anchorage component or by blocking synthesis of a migration inhibitor) remains to be established. While the detailed mechanism of action and cellular responses remains to be resolved the conclusion from these results is that for the icrovascular system perturbation of collagen related systems by low concentrations of proline analogues is sufficient to provoke cell migration and angiogenesis.
  • the present invention is capable of application in a wide variety of clinical fields.
  • Stimulation of angiogenesis can be used to enhance the healing of b ⁇ rns and wounds, especially those involving large tissue defects, acceptance of skin or organ grafts, and can also be used in reconstructive and cosmetic surgery, including the use of subdermal implants, .and in prosthetic surgery, particularly that involving vascular prostheses.
  • Such stimulation may be used in any situation wherein endothelial cell migration and regeneration of endothelium are advantageous, or where an increase in blood flow is desirable, e.g., stroke, heart disease, or foetal blood insufficiency.
  • This application of cis-HYPRO excludes its use as an agent which might improve the performance of implantable prosthetic devices such as pacemaker electrodes by virtue of properties other than stimulation of angiogenesis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un procédé de stimulation de l'angiogénèse chez les mammifères consiste à utiliser un modulateur de synthèse du collagène ou un ensemble de fibrilles de collagène. Le modulateur est de préférence un inhibiteur de l'enzyme proline hydroxylase. Le modulateur est de préférence choisi dans le groupe qui comprend de la cis-4-hydroxy-L-proline, de la 3,4-déhydro-L-proline, de l'acide L-azétidine-2-carboxylique, des composés analogues de L-proline et leurs composés analogues et leurs dérivés pharmacologiquement actifs. Ledit modulateur peut éventuellement être utilisé en association avec un second stimulateur de l'angiogénèse. Des compositions contenant lesdits modulateurs sont également décrites.
EP19870901278 1986-02-18 1987-02-10 Stimulation de l'angiogenese. Withdrawn EP0294380A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU4668/86 1986-02-18
AUPH466886 1986-02-18

Publications (2)

Publication Number Publication Date
EP0294380A1 true EP0294380A1 (fr) 1988-12-14
EP0294380A4 EP0294380A4 (fr) 1990-02-20

Family

ID=3771473

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19870901278 Withdrawn EP0294380A4 (fr) 1986-02-18 1987-02-10 Stimulation de l'angiogenese.

Country Status (3)

Country Link
EP (1) EP0294380A4 (fr)
JP (1) JPS63502661A (fr)
WO (1) WO1987004925A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01503705A (ja) * 1986-08-18 1989-12-14 ビオタ・シャンティフィック・マネージメント・ピーティーワイ・リミテッド 脈管形成の刺激および内皮化の増進
US5021404A (en) * 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators
JP2002516118A (ja) * 1998-05-29 2002-06-04 ウイスコンシン アラムニ リサーチ ファンデーション 細胞遊走調節のための物質および方法
CN111743885B (zh) * 2020-08-17 2022-03-15 山东省科学院生物研究所 一种对羟基苯乙酸在预防和/或治疗心血管疾病中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7639M (fr) * 1967-09-14 1970-02-02
GB1399887A (en) * 1971-06-10 1975-07-02 Prockop D J Composition and methods for controlling collagen synthesis
AU4336972A (en) * 1972-06-13 1973-12-20 Prockop D J Controlling collagen synthesis
CA1281288C (fr) * 1984-11-05 1991-03-12 Wilhelm Hoerrmann Traitement des tumeurs
DE3518078A1 (de) * 1985-05-20 1986-11-20 Wilhelm Dr. 8127 Iffeldorf Hoerrmann Arzneimittel, die derivate des prolin oder hydroxyprolin enthalten

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Am. J. Pathol., Vol. 106, 1982, pages 180-186, American Association of Pathologists, J.A. MADRI et al.: "Aortic endothelial cell migration", whole article, especially page 184. *
Am. J. Pathol., Vol. 112, No. 2, 1983, pages 224-230, American Association of Pathologists, I.Y.R. ADAMSON et al.: "Endothelial injury and repair in radiation-induced pulmonary fibrosis", whole article. *
Cell Biology International Reports, Vol. 9, No. 2, February 1985, pages 175-182, Academic Press Inc., London, GB; B.R. McAUSLAN et al.: "New functions of epidermal growth factor: stimulation of capillary endothelial cell migration and matrix dependent proliferation", whole article. *
Experimental and Molecular Pathology, Vol. 39, 1983, pages 219-229, Academic Press Inc., T.M. HERING et al.: "Type V collagen during granulation tissue development", whole article. *
Experimental Cell Research, Vol. 176, 1988, pages 248-257, Academic Press Inc., B.R. McAUSLAN et al.: "Induction of endothelial cell migration by proline analogs and its relevance to angiogenesis", whole article. *
Prog. Microcir. Res. (Proc. Austr. Symp. Microcirc.), 1st edition, 1981, pages 470-482, Ed. D. GARLICH et al., B.R. McAUSLAN et al.: "A new theory of neovascularisation and its relevance to the clinical use of aspirin", whole article. *
See also references of WO8704925A1 *
The Journal of Investigative Dermatology, Vol. 80, No. 4, 1983, pages 261-267, The Williams & Wilkins Co., E.M.L. TAN et al.: "Proline analogues inhibit human skin fibroblast growth and collagen production in culture", whole article. *
Transplantation, Vol. 36, No. 1, 1983, pages 1-6, The Williams & Wilkins Co., A. NEMLANDER et al.: "Effect of cyclosporine on wound healing", whole article. *

Also Published As

Publication number Publication date
WO1987004925A1 (fr) 1987-08-27
EP0294380A4 (fr) 1990-02-20
JPS63502661A (ja) 1988-10-06

Similar Documents

Publication Publication Date Title
Moses et al. Inhibitors of angiogenesis
Tron et al. Expression and modulation of nerve growth factor in murine keratinocytes (PAM 212).
Schultz et al. Effects of growth factors on corneal wound healing
JP3854307B2 (ja) 細胞外マトリックスの蓄積を防止するためのトランスフォーミング増殖因子βの阻害
Libby et al. Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells.
Mansbridge et al. Growth factors secreted by fibroblasts: role in healing diabetic foot ulcers.
Wong et al. Cyr61, product of a growth factor-inducible immediate-early gene, regulates chondrogenesis in mouse limb bud mesenchymal cells
EP0716610B1 (fr) Proteines morphogenetiques osseuses chez l'homme pour l'utilisation en regeneration nerveuse
Kenney et al. Increased gelatinolytic activity in keratoconus keratocyte cultures: a correlation to an altered matrix metalloproteinase-2/tissue inhibitor of metalloproteinase ratio
TWI257307B (en) Pharmaceutical composition for cardiac tissue repair
Coletta et al. Alteration in expression of MMP‐1 and MMP‐2 but not TIMP‐1 and TIMP‐2 in hereditary gingival fibromatosis is mediated by TGF‐β1 autocrine stimulation
Yokozeki et al. Transforming Growth Factor-β1 Modulates Myofibroblastic Phenotype of Rat Palatal Fibroblastsin Vitro
Nakamura et al. Differential effects of epidermal growth factor and interleukin 6 on corneal epithelial cells and vascular endothelial cells
EP0463152A1 (fr) Procede inhibiteur de l'angiogenese tumorale.
JP4568383B2 (ja) 血管形成の促進方法
KR20010075220A (ko) 비스포스포네이트와 테트라시클린의 배합물
WO1990012590A1 (fr) Traitement de maladies oculaires par modulation de metaloproteinases matricielles et leur inhibiteur
Tripathi et al. Prospects for epidermal growth factor in the management of corneal disorders
US5155038A (en) Use of thrombospondin to promote wound healing
Priglinger et al. Tissue transglutaminase as a modifying enzyme of the extracellular matrix in PVR membranes
EP0294380A1 (fr) Stimulation de l'angiogenese
Chen et al. Human recombinant transforming growth factor-β1 modulation of biochemical and cellular events in healing of ulcer wounds
US7517654B2 (en) Peptide and a derivative thereof promoting cell adhesion and spreading
WO1988001166A1 (fr) Stimulation de l'angiogenese et promotion de l'endothelialisation
Peacock Collagenolysis: The other side of the equation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19880817

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19900220

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19910903

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MCAUSLAN, BRIAN, RICHARD